{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:22:27Z","timestamp":1777576947068,"version":"3.51.4"},"reference-count":51,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["98242"],"award-info":[{"award-number":["98242"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN27201100016C"],"award-info":[{"award-number":["HHSN27201100016C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.00149","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T22:37:20Z","timestamp":1487716640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein\/Adjuvant HIV Vaccines in Two Immunization Regimes"],"prefix":"10.3389","volume":"8","author":[{"given":"Sarah","family":"Joseph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Killian","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldona","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alethea V.","family":"Cope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul F.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub T.","family":"Kopycinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleisha N.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Geldmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Nadai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed I. M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Len","family":"Dally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Bouliotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J. M.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Tatoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin J.","family":"Shattock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheena","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"issue":"1","key":"B1","doi-asserted-by":"publisher","first-page":"e0146387","DOI":"10.1371\/journal.pone.0146387","article-title":"Exploring the potential health impact and cost-effectiveness of AIDS vaccine within a comprehensive HIV\/AIDS response in low- and middle-income countries","volume":"11","author":"Harmon","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"B2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"B3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"12","key":"B4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"9653","key":"B5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"7","key":"B6","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1473-3099(11)70098-6","article-title":"Safety and efficacy of the HVTN 503\/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study","volume":"11","author":"Gray","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"22","key":"B7","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"B8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"B9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"B10","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"Bonsignori","year":"2012","journal-title":"J Virol"},{"issue":"22","key":"B11","doi-asserted-by":"publisher","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"228","key":"B12","doi-asserted-by":"publisher","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med"},{"issue":"9","key":"B13","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1172\/JCI75539","article-title":"FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial","volume":"124","author":"Li","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"B14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"Liao","year":"2013","journal-title":"Immunity"},{"issue":"14","key":"B15","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.1128\/JVI.00156-14","article-title":"HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities","volume":"88","author":"Pollara","year":"2014","journal-title":"J Virol"},{"issue":"2","key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.5863\/1551-6776-12.2.68","article-title":"A multi-vector, multi-envelope HIV-1 vaccine","volume":"12","author":"Hurwitz","year":"2007","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"12","key":"B17","doi-asserted-by":"publisher","first-page":"6138","DOI":"10.1128\/JVI.76.15.7625-7631.2002","article-title":"Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime\/recombinant modified Vaccinia virus Ankara vaccine","volume":"76","author":"Amara","year":"2002","journal-title":"J Virol"},{"issue":"3","key":"B18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"issue":"24","key":"B19","doi-asserted-by":"publisher","first-page":"12009","DOI":"10.1128\/JVI.01749-06","article-title":"Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity","volume":"80","author":"Thorner","year":"2006","journal-title":"J Virol"},{"issue":"50","key":"B20","doi-asserted-by":"publisher","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"B21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1586\/14760584.7.2.175","article-title":"Current progress of DNA vaccine studies in humans","volume":"7","author":"Lu","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"25","key":"B22","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1016\/j.vaccine.2008.02.072","article-title":"EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone","volume":"26","author":"McCormack","year":"2008","journal-title":"Vaccine"},{"issue":"1","key":"B23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20071331","article-title":"An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses","volume":"205","author":"Harari","year":"2008","journal-title":"J Exp Med"},{"key":"B24","author":"Levy","year":"2010"},{"issue":"9","key":"B25","doi-asserted-by":"publisher","first-page":"e0161753","DOI":"10.1371\/journal.pone.0161753","article-title":"Sequential immunization with gp140 boosts immune responses primed by modified vaccinia Ankara or DNA in HIV-uninfected South African participants","volume":"11","author":"Churchyard","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"B26","doi-asserted-by":"publisher","first-page":"e0131748","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA given with or without intradermal electroporation is safe and highly immunogenic in healthy Swedish HIV-1 DNA\/MVA vaccines: a phase I randomized trial","volume":"10","author":"Nilsson","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"B27","doi-asserted-by":"publisher","first-page":"e0152038","DOI":"10.1371\/journal.pone.0152038","article-title":"Comparative immunogenicity of HIV-1 gp140 vaccine delivered by parenteral, and mucosal routes in female volunteers; MUCOVAC2, a randomized two centre study","volume":"11","author":"Cosgrove","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"B28","doi-asserted-by":"publisher","first-page":"e0155702","DOI":"10.1371\/journal.pone.0155702","article-title":"Boosting with subtype C CN54rgp140 protein adjuvanted with glucopyranosyl lipid adjuvant after priming with HIV-DNA and HIV-MVA is safe and enhances immune responses: a phase I trial","volume":"11","author":"Joachim","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"B29","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"18","key":"B30","doi-asserted-by":"publisher","first-page":"9154","DOI":"10.1128\/JVI.00652-15","article-title":"An enhanced synthetic multiclade DNA prime induces improved cross-clade-reactive functional antibodies when combined with an adjuvanted protein boost in nonhuman primates","volume":"89","author":"Wise","year":"2015","journal-title":"J Virol"},{"issue":"12","key":"B31","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.1128\/JVI.00383-15","article-title":"Comparison of immunogenicity in rhesus macaques of transmitted-founder, HIV-1 group M consensus, and trivalent mosaic envelope vaccines formulated as a DNA prime, NYVAC, and envelope protein boost","volume":"89","author":"Hulot","year":"2015","journal-title":"J Virol"},{"issue":"8","key":"B32","doi-asserted-by":"publisher","first-page":"e41936","DOI":"10.1371\/journal.pone.0041936","article-title":"A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults","volume":"7","author":"Keefer","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"B33","doi-asserted-by":"publisher","first-page":"e25165","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally","volume":"6","author":"Lewis","year":"2011","journal-title":"PLoS One"},{"issue":"23","key":"B34","doi-asserted-by":"publisher","first-page":"11367","DOI":"10.1128\/JVI.74.23.11367-11376.2000","article-title":"Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C\/B\u2019) recombinant strain in China","volume":"74","author":"Su","year":"2000","journal-title":"J Virol"},{"issue":"8","key":"B35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1515\/hsz-2012-0148","article-title":"Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140","volume":"393","author":"Pabst","year":"2012","journal-title":"Biol Chem"},{"issue":"14","key":"B36","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.79.14.8828-8834.2005","article-title":"A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates","volume":"79","author":"Barouch","year":"2005","journal-title":"J Virol"},{"issue":"11","key":"B37","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.vaccine.2006.11.051","article-title":"Generation and immunogenicity of novel HIV\/AIDS vaccine candidates targeting HIV-1 Env\/Gag-Pol-Nef antigens of clade C","volume":"25","author":"Gomez","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"B38","doi-asserted-by":"publisher","first-page":"e35485","DOI":"10.1371\/journal.pone.0035485","article-title":"Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV\/AIDS of clade C","volume":"7","author":"Gomez","year":"2012","journal-title":"PLoS One"},{"key":"B39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","article-title":"Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1","volume":"409","author":"Sarzotti-Kelsoe","year":"2014","journal-title":"J Immunol Methods"},{"issue":"2","key":"B40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1128\/CVI.00326-08","article-title":"Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents","volume":"16","author":"Boaz","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"B41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets","volume":"79","author":"Roederer","year":"2011","journal-title":"Cytometry A"},{"issue":"4","key":"B42","doi-asserted-by":"publisher","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"Munseri","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"B43","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.immuni.2010.10.008","article-title":"From vaccines to memory and back","volume":"33","author":"Sallusto","year":"2010","journal-title":"Immunity"},{"issue":"3","key":"B44","doi-asserted-by":"publisher","first-page":"CD005530","DOI":"10.1002\/14651858.CD005530.pub2","article-title":"Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB)","author":"Bar-On","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"B45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2172-9-15","article-title":"Dendritic cells are preferentially targeted among hematolymphocytes by modified Vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo","volume":"9","author":"Liu","year":"2008","journal-title":"BMC Immunol"},{"issue":"10","key":"B47","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1128\/JVI.00264-12","article-title":"Modified Vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation","volume":"86","author":"Guzman","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"B48","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.virol.2006.02.039","article-title":"Infection of human dendritic cells with recombinant Vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity","volume":"350","author":"Kastenmuller","year":"2006","journal-title":"Virology"},{"issue":"14","key":"B49","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1001\/jama.293.14.1751","article-title":"Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial","volume":"293","author":"Buttery","year":"2005","journal-title":"JAMA"},{"issue":"2","key":"B50","doi-asserted-by":"publisher","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"B51","doi-asserted-by":"publisher","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T22:37:24Z","timestamp":1487716644000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fimmu.2017.00149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":51,"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.00149","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]}}}